Syndax Pharmaceuticals SNDX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's total liabilities?
- Syndax Pharmaceuticals (SNDX) reported total liabilities of $431.05M in Q1 2026.
- How has Syndax Pharmaceuticals's total liabilities changed year-over-year?
- Syndax Pharmaceuticals's total liabilities increased by 1.3% year-over-year, from $425.65M to $431.05M.
- What is the long-term trend for Syndax Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total liabilities has grown at a 57.2% compound annual growth rate (CAGR), from $48.43M to $465.08M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.